Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A multi-stakeholder multicriteria decision analysis for the reimbursement of orphan drugs (FinMHU-MCDA study).
de Andrés-Nogales F, Cruz E, Calleja MÁ, Delgado O, Gorgas MQ, Espín J, Mestre-Ferrándiz J, Palau F, Ancochea A, Arce R, Domínguez-Hernández R, Casado MÁ; FinMHU-MCDA Group. de Andrés-Nogales F, et al. Orphanet J Rare Dis. 2021 Apr 26;16(1):186. doi: 10.1186/s13023-021-01809-1. Orphanet J Rare Dis. 2021. PMID: 33902672 Free PMC article.
A Multiple Stakeholder Multicriteria Decision Analysis in Diabetic Macular Edema Management: The MULTIDEX-EMD Study.
de Andrés-Nogales F, Casado MÁ, Trillo JL, Ruiz-Moreno JM, Martínez-Sesmero JM, Peralta G, Poveda JL, Ortiz P, Ignacio E, Zarranz-Ventura J, Udaondo P, Mur C, Álvarez E, Cervera E, Martínez M, Llorente I, Zulueta J, Rodríguez-Maqueda M, García-Layana A, Martínez-Olmos J. de Andrés-Nogales F, et al. Pharmacoecon Open. 2020 Dec;4(4):615-624. doi: 10.1007/s41669-020-00201-2. Pharmacoecon Open. 2020. PMID: 32100249 Free PMC article.
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain.
Taxonera C, de Andrés-Nogales F, García-López S, Sánchez-Guerrero A, Menchén B, Peral C, Cábez A, Gómez S, López-Ibáñez de Aldecoa A, Casado MÁ, Menchén L. Taxonera C, et al. Among authors: de andres nogales f. Expert Rev Pharmacoecon Outcomes Res. 2022 Jan;22(1):73-83. doi: 10.1080/14737167.2021.1880324. Epub 2021 Feb 20. Expert Rev Pharmacoecon Outcomes Res. 2022. PMID: 33615953
Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.
Navarro F, Martinez-Sesmero JM, Balsa A, Peral C, Montoro M, Valderrama M, Gómez S, de Andrés-Nogales F, Casado MA, Oyagüez I. Navarro F, et al. Among authors: de andres nogales f. Clin Rheumatol. 2020 Oct;39(10):2919-2930. doi: 10.1007/s10067-020-05087-3. Epub 2020 Apr 17. Clin Rheumatol. 2020. PMID: 32303858 Free PMC article.
[Cost analysis of the use of botulinum toxin type A in Spain].
de Andrés-Nogales F, Morell A, Aracil J, Torres C, Oyagüez I, Casado MA. de Andrés-Nogales F, et al. Farm Hosp. 2014 May 1;38(3):193-201. doi: 10.7399/fh.2014.38.3.1163. Farm Hosp. 2014. PMID: 24951903 Free article. Spanish.
Cost-effectiveness of mechanical thrombectomy using stent retriever after intravenous tissue plasminogen activator compared with intravenous tissue plasminogen activator alone in the treatment of acute ischaemic stroke due to large vessel occlusion in Spain.
de Andrés-Nogales F, Álvarez M, de Miquel MÁ, Segura T, Gil A, Cardona P, Casado MÁ, Nogueira RG, Dávalos A. de Andrés-Nogales F, et al. Eur Stroke J. 2017 Sep;2(3):272-284. doi: 10.1177/2396987317721865. Epub 2017 Aug 1. Eur Stroke J. 2017. PMID: 31008321 Free PMC article.
12 results